Subtopic Deep Dive
ACE2 in Cardiovascular Pathology
Research Guide
What is ACE2 in Cardiovascular Pathology?
ACE2 in Cardiovascular Pathology examines angiotensin-converting enzyme 2's counter-regulatory role in the renin-angiotensin system, its downregulation in heart failure, and contributions to inflammation, fibrosis, and COVID-19 cardiovascular effects.
ACE2 degrades angiotensin II to angiotensin 1-7, balancing RAS pro-inflammatory effects (Tikellis and Thomas, 2012, 640 citations). Downregulation occurs in heart failure, exacerbating pathology (South et al., 2020, 786 citations). Over 10 key papers from 2005-2020 span foundational protection mechanisms to COVID-19 implications.
Why It Matters
ACE2 modulation protects against lung failure and cardiovascular damage in infections, as shown in avian influenza and SARS-CoV-2 models (Imai et al., 2005, 2532 citations; South et al., 2020). In heart failure, ACE2 activators counter RAS imbalance, reducing fibrosis and inflammation (Tikellis and Thomas, 2012). COVID-19 studies link ACE2 downregulation to worse CVD outcomes, guiding therapies like RAS inhibitors (Cheng et al., 2020, 550 citations; Pacurari et al., 2014).
Key Research Challenges
ACE2 Downregulation Mechanisms
Heart failure reduces ACE2 expression, shifting RAS toward angiotensin II dominance and promoting fibrosis (Tikellis and Thomas, 2012). Mechanisms involve inflammation and oxidative stress, complicating restoration (South et al., 2020). Therapies must target tissue-specific downregulation without infection risks.
COVID-19 Cardiovascular Risks
SARS-CoV-2 binds ACE2, depleting it in CVD patients and worsening heart pathology (South et al., 2020, 786 citations). Balancing antiviral protection with RAS therapy remains unresolved (Cheng et al., 2020). Inflammation amplifies thrombosis and failure risks.
Developing ACE2 Activators
Activators must enhance Ang(1-7) without increasing viral entry (Imai et al., 2005). Clinical translation faces specificity and safety hurdles in chronic CVD (Tikellis and Thomas, 2012). Kallikrein-kinin interactions add complexity (Moreau et al., 2005).
Essential Papers
Angiotensin-converting enzyme 2 protects from severe acute lung failure
Yumiko Imai, Keiji Kuba, Shuan Rao et al. · 2005 · Nature · 2.5K citations
COVID-19, ACE2, and the cardiovascular consequences
Andrew M. South, Debra I. Diz, Mark C. Chappell · 2020 · American Journal of Physiology-Heart and Circulatory Physiology · 786 citations
The novel SARS coronavirus SARS-CoV-2 pandemic may be particularly deleterious to patients with underlying cardiovascular disease (CVD). The mechanism for SARS-CoV-2 infection is the requisite bind...
Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease
Chris Tikellis, Merlin C. Thomas · 2012 · International Journal of Peptides · 640 citations
Angiotensin-converting enzyme 2 (ACE2) shares some homology with angiotensin-converting enzyme (ACE) but is not inhibited by ACE inhibitors. The main role of ACE2 is the degradation of Ang II resul...
Organ‐protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19
Hao Cheng, Yan Wang, Gui‐Qiang Wang · 2020 · Journal of Medical Virology · 550 citations
Abstract This article reviews the correlation between angiotensin‐converting enzyme 2 (ACE2) and severe risk factors for coronavirus disease 2019 (COVID‐19) and the possible mechanisms. ACE2 is a c...
The Kallikrein-Kinin System: Current and Future Pharmacological Targets
Marie Eve Moreau, Nancy Garbacki, Giuseppe A. Molinaro et al. · 2005 · Journal of Pharmacological Sciences · 457 citations
The kallikrein-kinin system is an endogenous metabolic cascade, triggering of which results in the release of vasoactive kinins (bradykinin-related peptides). This complex system includes the precu...
Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections
Zhen Zou, Yiwu Yan, Yuelong Shu et al. · 2014 · Nature Communications · 418 citations
The renin‐angiotensin‐aldosterone system and its suppression
Marisa K. Ames, Clarke E. Atkins, Bertram Pitt · 2019 · Journal of Veterinary Internal Medicine · 411 citations
Chronic activation of the renin‐angiotensin‐aldosterone system (RAAS) promotes and perpetuates the syndromes of congestive heart failure, systemic hypertension, and chronic kidney disease. Excessiv...
Reading Guide
Foundational Papers
Start with Imai et al. (2005, 2532 citations) for ACE2 protection mechanisms in acute failure; then Tikellis and Thomas (2012, 640 citations) for core RAS modulation role.
Recent Advances
Study South et al. (2020, 786 citations) for COVID-19 cardiovascular links; Cheng et al. (2020, 550 citations) for organ protection and prognosis.
Core Methods
Core techniques: ACE2 knockout mice for pathology (Imai et al., 2005); angiotensin peptide assays (Tikellis and Thomas, 2012); cohort analysis of expression in CVD/COVID (South et al., 2020).
How PapersFlow Helps You Research ACE2 in Cardiovascular Pathology
Discover & Search
Research Agent uses searchPapers and exaSearch to find ACE2 papers like 'Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator...' by Tikellis and Thomas (2012), then citationGraph reveals 640 citing works on CVD pathology, while findSimilarPapers uncovers related RAS imbalance studies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract ACE2 downregulation data from South et al. (2020), verifies claims via verifyResponse (CoVe) against Imai et al. (2005), and runs PythonAnalysis for statistical correlation of citations with heart failure metrics using pandas, with GRADE grading for evidence strength in RAS modulation.
Synthesize & Write
Synthesis Agent detects gaps in ACE2-COVID therapies via contradiction flagging across Cheng et al. (2020) and Pacurari et al. (2014), while Writing Agent uses latexEditText, latexSyncCitations for Tikellis (2012), and latexCompile to generate review sections with exportMermaid for RAS pathway diagrams.
Use Cases
"Run statistical analysis on ACE2 expression correlations in heart failure datasets from top papers."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/matplotlib on extracted data from Tikellis 2012) → correlation plots and p-values output.
"Draft LaTeX review on ACE2 role in COVID-19 cardiovascular effects."
Research Agent → citationGraph (South 2020 cluster) → Synthesis → gap detection → Writing Agent → latexEditText + latexSyncCitations + latexCompile → formatted PDF with figures.
"Find GitHub code for ACE2-RAS simulation models from related papers."
Research Agent → paperExtractUrls (Pacurari 2014) → Code Discovery → paperFindGithubRepo → githubRepoInspect → verified simulation scripts for inflammation modeling.
Automated Workflows
Deep Research workflow scans 50+ ACE2 papers via searchPapers → citationGraph → structured report on pathology mechanisms (Imai 2005 to Cheng 2020). DeepScan applies 7-step analysis with CoVe checkpoints to verify downregulation claims in South et al. (2020). Theorizer generates hypotheses on ACE2 activators from RAS literature gaps.
Frequently Asked Questions
What defines ACE2's role in cardiovascular pathology?
ACE2 counter-regulates RAS by converting angiotensin II to angiotensin 1-7, protecting against inflammation and fibrosis, but downregulates in heart failure (Tikellis and Thomas, 2012).
What methods study ACE2 in this subtopic?
Studies use knockout models for lung/heart protection (Imai et al., 2005), expression analysis in COVID-19 cohorts (South et al., 2020), and RAS peptide quantification (Tikellis and Thomas, 2012).
What are key papers on ACE2 in cardiovascular pathology?
Top papers: Imai et al. (2005, 2532 citations) on protection; South et al. (2020, 786 citations) on COVID-19 CVD; Tikellis and Thomas (2012, 640 citations) on RAS modulation.
What open problems exist?
Challenges include safe ACE2 upregulation without viral risks, tissue-specific therapies for heart failure fibrosis, and resolving COVID-19 ACE2 depletion effects (Cheng et al., 2020; South et al., 2020).
Research Renin-Angiotensin System Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching ACE2 in Cardiovascular Pathology with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Renin-Angiotensin System Studies Research Guide